STUDresearch · Peptide
Sigumir
Also known as
Sigumir peptide · cartilage-bone bioregulator
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
Oral
Organ bioregulators
Cartilage/joint-framed oral extract; organ-targeting language does not establish selective human delivery.
What people say
Sigumir is an animal-cartilage low-molecular-weight peptide extract, not a single sequence-defined peptide or the AED tripeptide Cartalax.
Doses people talk about
The named product is an animal-tissue extract whose composition and retail identity may vary. Community authors, outcomes and changing amounts remain separate.
How it may feel
The small inspected discussion conflicts: one author found nothing exciting after a month, while a separate author described more solid knees after a changing full-box course.
Opening-author account2 capsules oral daily for one month
The same author later reported nothing exciting and then moved on to PRP; capsule content was not independently verified.
Separate full-box account4 capsules twice daily initially; later 3 daily, then “2 per”
The author reported more solid knees, but the later wording is ambiguous and the sequence cannot be treated as a stable regimen.
Originating brochure program10 mg oral capsules; 1–3 capsules 2–3 times daily for 30–45 days
Promotional introduction, not controlled dose-ranging: 10–15 minutes before meals. The brochure’s described main group used 2–3 capsules 2–3 times daily; neither is an independent recommendation.
Half-life & effect duration
- Half-life in the body
- Cartilage-derived peptide complexNo settled estimate
- Felt duration people report
- One accountNothing exciting after 1 month
- Another accountMore solid-feeling knees across a full box
Cycles people discuss
Legacy material describes short seasonal courses, but no controlled comparison establishes an on/off schedule.
Timing
Legacy notes organize timing around tolerability, training and sleep; the originating oral program uses before-meal timing, not a measured onset target.
Stacks
A solo course is easier to interpret than a multi-bioregulator stack; the preserved notes do not establish a validated combination.
Watch for
Unknowns: Long-term safety for gray-market preparations is often poorly characterized.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No rigorous human half-life or exposure profile was established for the named animal-cartilage extract.
The originating brochure supplies composition and course language, while the small 2012 human report evaluates Sigumir only within a combined treatment program.
A multi-component tissue extract, promotional source and combined-treatment abstract do not establish parent pharmacokinetics or isolated Sigumir effects; the full Russian paper was not independently read.
- Khavinson-origin clinical research brochure for Cytomaxes and Cytogens (opens in a new tab)PDF pages 52–54 (zero-based 51–53): cartilage peptide complex up to 5000 Da from young calves or pigs; 10 mg capsules/tablets. Page 52 introduction lists 1–3 capsules 2–3 times/day for 30–45 days, 10–15 minutes before meals; its described main group used 2–3 capsules 2–3 times/day. These are originating promotional combined-treatment descriptions.Originating promotional brochure, not independent product characterization, randomized dose-ranging evidence or a pharmacokinetic study.
- Iordanishvili et al. (2012): Sigumir in combined treatment of temporomandibular-joint disease (opens in a new tab)Indexed abstract and author list, accessed through Europe PMC: 62 older patients with temporomandibular-joint disease; combined treatment included Sigumir, dental prosthetics, functional and pharmacological treatment, including treatment for accompanying disease. Vesugen is not named. The abstract reports clinical/laboratory outcomes, not PK.Small combined-treatment abstract; no isolated Sigumir causality or PK conclusion is supported. Full Russian text was not independently read, and randomization/control details are not inferred from the abstract.
- Sigumir evidence review and identity distinction (opens in a new tab)Identity and evidence sections reviewed: distinguishes the natural cartilage extract Sigumir from the AED tripeptide Cartalax and notes the absence of registered Sigumir trials.Secondary evidence review, not primary analytical chemistry, trial registration authority or independent batch testing.
Felt duration people report
The small inspected discussion contains one null month and one separate subjective joint-improvement report, without a reliable onset timeline.
The opening author dkranj reported nothing exciting after two capsules daily for a month, then moved on to PRP. Separately, me-i-am described more solid knees after changing amounts across a full box. Neither course establishes a characteristic day-one onset; inherited early-window notes remain qualified separately.
Distinct authors, unverified product identity and capsule content, uncontrolled co-interventions and very low report volume; no prevalence or causal duration can be inferred.
- Ordered Sigumir community thread (opens in a new tab)Opening thread and visible author follow-ups: dkranj later reported two capsules daily for one month with nothing exciting, then PRP; me-i-am separately described four capsules twice daily initially, later three daily then ambiguous “2 per,” and more solid knees across a full box. dkranj also repeats retail 10-day/month/three-month-repeat language. The inspected thread does not establish a separate day-2 account.Small uncontrolled multi-author discussion, unverified products and capsule content, ambiguous later dose wording and co-interventions; authors were kept separate.
What people say
- cartilage / joints narrative: Community and regional literature frame benefits around cartilage / joints function and “normalization” language. forum
- What is thinner: Large modern multi-center RCTs are often absent for the specific peptide brand story. forum
- Organ-target lore: Sigumir is sold in Khavinson-style catalogs for a specific organ/system story rather than a systemic “GH peptide” narrative. forum
- Course culture: Users often describe multi-day to multi-week capsule courses, then breaks — more “seasonal tune-up” than daily forever. forum
- Subtlety claims: Benefits, when claimed, are usually mild (comfort, “support,” recovery feel) and hard to separate from sleep/diet. anecdote
Doses people talk about
- Retail course charts: cartilage/joint bioregulator retail courses often 10 mg capsules multi-week. Exact brands differ. forum
- Duration talk / originating program: Inherited vendor literature describes 10–30-day courses, sometimes repeated 2–3×/year; a forum retail comment separately mentions 10 days for minor issues, a month for major issues and repetition after three months. The originating promotional brochure instead lists 10 mg capsules/tablets, an introductory 1–3 capsules 2–3 times daily for 30–45 days, 10–15 minutes before meals; its described main group used 2–3 capsules 2–3 times daily. These are distinct retail and combined-treatment program descriptions, not controlled dose-ranging results. forumtrial
- Honesty: these are marketing-course numbers, not robust Western RCTs for every named product. forum
- Framing: Khavinson-style organ peptide / bioregulator retail culture — not FDA-approved disease therapy. forum
How it may feel
- Days 1–7 / one-month account: Inherited bioregulator notes describe conditional injection-site reactions or oral GI/mood shifts before benefits. This is generic legacy tolerability discussion, not an established first-week pattern for the originating oral Sigumir extract. Separately, dkranj later reported two capsules daily for one month with nothing exciting, then moved on to PRP. forumanecdote
- Courses / separate full-box account: Inherited bioregulator culture describes 10–20-day courses repeated a few times per year; this is not a validated Sigumir calendar. A different commenter, me-i-am, described changing amounts across a box—initially four capsules twice daily, later three daily, then “2 per”—and subjectively called their knees more solid. The later wording is ambiguous and the course is separate from dkranj’s null month. forumanecdote
- Day 1: Inherited generic bioregulator notes emphasize route logistics, possible sting or GI effects rather than a “miracle” effect. These are not evidence of a characteristic Sigumir day-one response or of an injectable version of the originating oral extract; the inspected main accounts do not establish that early window. forum
- Days 2–7: Inherited notes treat the first week as a general side-effect observation window across agents and caution that any benefits are easy to misattribute. This is legacy attribution/tolerability context, not an observed prevalence pattern for Sigumir. forum
- Weeks 1–2 / later outcomes: Inherited self-log culture uses weeks 1–2 as an early checkpoint, not a validated onset target. The inspected later accounts conflict: dkranj reported nothing exciting after a month, while me-i-am separately reported subjectively more solid knees after a changing full-box course. forum
Cycles people discuss
- Course culture: Short on, long off, repeat seasonally is the common pattern. forum
- Common pattern: Many self-protocols use weeks-on / weeks-off rather than indefinite daily use — cost and caution drive this more than hard science. forum
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
Timing
- Short peptides: Rapid clearance assumed; course timing matters more than steady plasma levels in lore. forum
- Timing practicalities: Legacy notes organize timing around side effects, training and sleep more than perfect PK. Separately, the originating promotional oral program describes 10–15-minute before-meal timing, which is administration context rather than a measured onset or exposure target. forumtrial
- PK honesty: Sigumir bioregulator products rarely publish rigorous human PK packages in English literature. forum
More on what it is
- Evidence honesty: Much of the English-web discussion is secondary summaries and vendor literature; treat claims cautiously. forum
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for Sigumir, not proof it works for you. forum
- What it is: Sigumir is described by its originating materials as a mixture of low-molecular-weight peptides (up to 5000 Da) isolated from cartilage tissue of young calves or pigs. It is not a single sequence-defined peptide and must not be confused with the AED tripeptide Cartalax. trial
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- Multi-bioregulator stacks: Often combined by organ system in protocols. forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Generally mild claims: Vendor literature often claims good tolerability — independent long-term data limited. forum
- Allergy / unknown impurities: Gray-market risk. forum
- Injection site (if injected): Redness, itch, lumps, bruise — technique and product quality matter. This is a retained general legacy injection warning, not evidence that the originating oral Sigumir cartilage-extract capsule is injectable. Source tissue, composition and batch consistency also remain material uncertainties for an animal-cartilage mixture. forumtrial
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.